Photo Credit: Raimundo79

The following is a summary of “Diagnostic and prognostic utility of bone morphogenetic protein 10 in acute dyspnea: a cohort study,” published in the December 2024 issue of Cardiology by Simonavicius et al.  

Bone Morphogenetic Protein 10 (BMP10) is a novel atrial-specific biomarker, and the clinical utility in diagnosing and predicting outcomes in individuals with acute dyspnea remains unclear.  

Researchers conducted a prospective study evaluating the diagnostic and prognostic accuracy of BMP10 in individuals presenting with acute dyspnea.  

They assessed BMP10, high-sensitivity cardiac troponin T (hs-cTnT), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with acute dyspnea at EDs. The final diagnosis was determined by 2 independent cardiologists blinded to BMP10 (n=933). The diagnostic accuracy for acute heart failure (AHF) was assessed using the area under the receiver operating characteristic curve (AUC), 720-day all-cause mortality, and a composite of all-cause mortality or AHF rehospitalization were measured as prognostic outcomes.  

The results showed that individuals with AHF had higher BMP10 levels (median 3.34 ng/mL [IQR 2.55–4.35]) compared to individuals with other causes of acute dyspnea (2.04 ng/mL [1.74–2.45], P<0.001). The BMP10 had a diagnostic AUC of 0.85 (95% CI, 0.82–0.87), compared to 0.79 (95% CI, 0.76–0.82, P<0.001) for hs-cTnT and 0.91 (95% CI, 0.90–0.93, P<0.001) for NT-proBNP. Combining BMP10 with NT-proBNP resulted in an AUC of 0.92 (95% CI, 0.90–0.94), which did not improve the diagnostic accuracy compared to NT-proBNP alone, BMP10 predicted death and AHF rehospitalization, but offered no added value to NT-proBNP in prognostic models.  

They concluded that BMP10 showed high diagnostic accuracy for AHF and was a strong predictor of death and rehospitalization but did not provide additional value over NT-proBNP.  

Source: link.springer.com/article/10.1007/s00392-024-02584-2